A Study Evaluating the Prevalence, Incidence and Predictors for Development of the Impulse Control Disorders in Patients with Prolactinomas Treated with Dopamine Agonist Therapy


About this study

The purpose of this study is to establish incidence and prevalence of Impulse Control Disorders (ICDs) in patients with prolactinomas treated with dopamine agonists (DA), to determine the predictors of ICD development, and to establish a predictor scoring system that could be subsequently validated and applied prior to initiation of DA.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Age 18 years old and above.
  • Diagnosis of prolactinoma.
  • Ability to provide informed consent.

Exclusion Criteria:

  • None.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Irina Bancos, M.D.

Open for enrollment

Contact information:

Vanessa Fell

(507) 266-6068


Jacksonville, Fla.

Mayo Clinic principal investigator

Sarika Rao, D.O.

Closed for enrollment

Contact information:

Melinda Thomas


More information


Publications are currently not available

Mayo Clinic Footer